CerebrolysinvsSemax

Cerebrolysin is a complex biological preparation consisting of low-molecular-weight neuropeptides (approximately 75%) and free amino acids (approximately 25%), derived from enzymatic breakdown of porcine brain tissue. The peptide fraction contains fragments that mimic the activity of endogenous neurotrophic factors — BDNF, NGF, ciliary neurotrophic factor (CNTF), and glial cell line-derived neurotrophic factor (GDNF) — without being identical to any single neurotrophin.

The neurotrophic peptide components activate canonical neurotrophin signaling pathways. BDNF-mimetic peptides bind TrkB receptors, activating PI3K/Akt (cell survival) and Ras/MAPK/ERK (synaptic plasticity) cascades. NGF-mimetic peptides activate TrkA receptors on cholinergic neurons, supporting their survival and acetylcholine production. The combined neurotrophic activity promotes neuronal survival in ischemic and degenerative conditions, enhances synaptic plasticity and dendritic branching, and stimulates neurogenesis in the subgranular zone of the hippocampal dentate gyrus — one of the two brain regions where new neurons are produced in adults.

In Alzheimer's disease, Cerebrolysin has demonstrated multiple disease-modifying effects in preclinical and clinical studies. It reduces amyloid-beta aggregation by modulating the activity of amyloid precursor protein (APP) processing enzymes, shifting cleavage toward the non-amyloidogenic alpha-secretase pathway. It also reduces tau hyperphosphorylation by inhibiting glycogen synthase kinase-3β (GSK-3β) and cyclin-dependent kinase 5 (CDK5), the primary kinases responsible for the pathological phosphorylation of tau that leads to neurofibrillary tangle formation. In acute stroke, Cerebrolysin provides neuroprotection against glutamate excitotoxicity by modulating NMDA receptor activity — reducing excessive calcium influx through the receptor while preserving physiological glutamatergic signaling needed for normal neuronal function. Its approval in over 50 countries and large clinical evidence base (including meta-analyses of randomized controlled trials) make it one of the most clinically validated neuropeptide preparations, despite its lack of FDA approval.

Semax is a synthetic heptapeptide consisting of the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) — the shortest sequence of ACTH that retains neurotrophic activity — with a Pro-Gly-Pro C-terminal extension for proteolytic stability. Crucially, it contains only the neurotrophic portion of ACTH without the N-terminal amino acids (residues 1-3) required for adrenal cortex stimulation, so it has no effect on cortisol production or the HPA stress axis.

Semax's primary nootropic mechanism is upregulation of neurotrophic factors in the hippocampus and cortex. It increases expression of brain-derived neurotrophic factor (BDNF) — the most important neurotrophin for learning and memory — through activation of the TrkB receptor signaling cascade (Ras/MAPK and PI3K/Akt pathways). BDNF promotes dendritic spine formation, enhances long-term potentiation (the cellular basis of memory), and supports neuronal survival. Semax also upregulates nerve growth factor (NGF), which maintains cholinergic neurons in the basal forebrain — the same neurons that degenerate in Alzheimer's disease and are critical for attention and memory.

At the neurotransmitter level, Semax modulates three monoamine systems. It enhances dopaminergic transmission in the prefrontal cortex and striatum, improving motivation, reward processing, and executive function. It modulates serotonergic activity (5-HT) in the raphe nuclei and limbic system, affecting mood and emotional regulation. It also enhances noradrenergic signaling from the locus coeruleus, improving alertness, focused attention, and working memory. The noradrenergic effect may be particularly relevant for its clinical use in ADHD-like conditions and attention disorders. In stroke recovery (an approved indication in Russia), Semax provides neuroprotection through multiple mechanisms: BDNF-mediated anti-apoptotic signaling, reduction of glutamate excitotoxicity, decreased oxidative stress, and maintenance of blood-brain barrier integrity in the peri-infarct region.